Business
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio choleraeCrofelemer previously granted Orphan Drug
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio choleraeCrofelemer previously granted Orphan Drug Designation by the FDA and the EMA for both short bowel syndrome and microvillus inclusion diseaseSAN FRANCISCO, CA / ACCESSWIRE / February 12, 2024 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has submitted an Orphan Drug Designation (ODD) application to the U.S. Food and Drug Administration (FDA) for crofelemer, the company's novel plant-based prescription drug, for the symptomatic relief and treatment of moderate-to-severe diarrhea, with or without concomitant antimicrobial therapy, from bacterial, viral, and parasitic infections including Vibrio cholerae, the bacterium that causes cholera.Due to the very low incidence and prevalence of cholera in the United States, cholera is an orphan indication in this country. Rare diseases, also referred to as orphan indications, are a core Jaguar development focus. In 2024 and 2025, Jaguar expects results from 5 proof-of-concept studies of crofelemer, the company's novel plant-based prescription drug, from at least 8 clinical sites, including Cleveland Clinic, on three continents for the rare disease indications of microvillus inclusion disease (MVID) - an ultrarare congenital diarrheal disorder (CDD) - and short bowel syndrome (SBS). In accordance with the guidelines of specific European Union countries, published data from such clinical investigations could support reimbursed early patient access to crofelemer for these debilitating conditions in 2025 while the company pursues approval of crofelemer for SBS and MVID from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). In August 2023 the FDA activated Napo's Investigational New Drug (IND) application for a new crofelemer powder for oral solution formulation for the treatment of MVID.\"We are very pleased that the ODD application for crofelemer for cholera-related diarrhea has been submitted,\" said Steven King, PhD, Jaguar's Chief Sustainable Supply, Ethnobotanical Research & IP Officer. \"The company previously presented Phase 2 data on crofelemer for the treatment of devastating dehydration in cholera patients from the renowned International Centre for Diarrhoeal Disease Research (icddr,b) in B...